Welcome to our dedicated page for Brainsway Ltd. SEC filings (Ticker: BWAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BrainsWay Ltd. (BWAY) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on NASDAQ and the Tel Aviv Stock Exchange. BrainsWay files reports with the U.S. Securities and Exchange Commission primarily on Form 20-F and Form 6-K, which together give investors insight into its Deep TMS™ business, financial condition, and material developments.
BrainsWay’s Form 20-F annual report contains audited financial statements, risk factors, a description of its Deep TMS platform and indications, and details on its operations in the United States and Israel. Interim and event-driven updates are furnished on Form 6-K, which the company often uses to submit press releases and investor materials covering topics such as FDA clearances, payer coverage expansions, clinical trial launches, NIH grants, strategic investments, shareholder meeting results, and quarterly financial results.
While BrainsWay’s filings are not structured as 10-K or 10-Q reports because it is a foreign issuer, investors can use the available 20-F and 6-K documents to answer many of the same questions: how the company describes its Deep TMS technology, what indications are cleared, how it reports revenue from leasing and selling systems, and what risks it highlights in relation to mental health and addiction treatment markets. Filings may also reference registration statements on Form F-3 and Form S-8, which relate to capital-raising and equity compensation arrangements.
On Stock Titan, BrainsWay filings are updated in near real time from EDGAR, and each document can be reviewed alongside AI-generated summaries that explain key points in accessible language. Users can quickly scan 6-K exhibits for new clinical, regulatory, or financial information, and then drill into the full text when deeper analysis is needed. This structure helps investors follow BWAY’s evolving regulatory and financial narrative without manually parsing every filing line by line.
BrainsWay Ltd. filed a Form 6-K to share that Highmark Blue Cross Blue Shield, which covers over seven million lives, has issued a draft medical policy to expand coverage for its accelerated Deep TMS™ protocol for major depressive disorder in both adolescents and adults. The draft policy is anticipated to take effect in February 2026 after an open comment period and would cover BrainsWay’s SWIFT™ protocol, a short-course regimen totaling 38 treatment sessions without requiring functional MRI or other costly neuronavigation equipment.
The company notes that this follows adoption of a similar medical policy by another payer and positions accelerated Deep TMS as a more convenient option requiring fewer clinic visits. BrainsWay’s accelerated depression protocol received FDA clearance in September 2025, supported by a multisite randomized trial showing an 87.8% response rate and 78.0% remission rate, with outcomes comparable to standard Deep TMS treatment.
BrainsWay Ltd. submitted a current report for January 2026 that centers on a regulatory milestone related to depression treatment. The report attaches a press release titled “BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD).” This indicates that the U.S. Food and Drug Administration has approved Neurolief’s Proliv™Rx neuromodulation system specifically for treating major depressive disorder. The filing also notes that this report is incorporated by reference into BrainsWay’s existing Form S-8 and Form F-3 registration statements.
BrainsWay Ltd. submitted a foreign issuer report providing an update related to its Deep TMS technology. The report mainly serves to furnish an exhibit titled “BrainsWay Reports Expansion of Adolescent Depression Coverage Applicable to Deep TMS,” indicating the company is reporting an expansion of coverage for adolescent depression treatment using its Deep TMS system. The 6-K is also incorporated by reference into BrainsWay’s existing Form S-8 and Form F-3 registration statements.
BrainsWay Ltd. (BWAY) submitted a Form 6-K as a foreign private issuer, incorporating this report into its existing Form S-8 and Form F-3 registration statements filed in 2019, 2024, and 2025.
The report includes an exhibit titled “BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder.” This indicates that the company has begun its first clinical trial using the Deep TMS 360 system in the area of alcohol use disorder.
BrainsWay Ltd. furnished a Form 6-K reporting that it received FDA clearance for its Deep TMS therapy as an adjunct treatment for major depressive disorder (MDD) in adolescents aged 15 to 21. The update is provided as an exhibit to the report. The company also notes that this Form 6-K is incorporated by reference into its existing U.S. registration statements on Form S-8 and Form F-3.
BrainsWay Ltd. (BWAY) furnished a Form 6-K for November 2025, providing an Investor Deck as Exhibit 99.1. The report notes that the submission is a foreign private issuer filing under the Securities Exchange Act.
The company states that this Form 6-K is incorporated by reference into its existing registration statements: a Form S-8 filed April 22, 2019 and Forms F-3 filed July 22, 2024 and April 22, 2025. The filing itself contains no financial results or transaction details beyond the inclusion of the investor presentation.
BrainsWay Ltd. furnished a Form 6-K. The filing includes an exhibit announcing a National Institutes of Health grant to a leading U.S. research team investigating accelerated Deep TMS for treatment of alcohol use disorder.
The report states this Form 6-K is incorporated by reference into the company’s Form S-8 and two Form F-3 registration statements.
Brainsway Ltd. reported the appointment of Kost Forer Gabbay & Kasierer, a certified public accounting firm in Israel and a member of Ernst & Young Global, as the companys independent auditors for 2025 and continuing until the next annual general meeting. The Board of Directors is authorized to set the auditors compensation. The filing records a vote tally of 19,070,493 and includes the signature of Ami Boehm.
FAQ
What is the current stock price of Brainsway Ltd. (BWAY)?
What is the market cap of Brainsway Ltd. (BWAY)?
